MX2017015235A - Composiciones para el tratamiento de vaginitis atrofica, dispareunia peri- y posmenopausica, y/o mujeres ooforectomizadas y metodos de tratamiento con las mismas. - Google Patents

Composiciones para el tratamiento de vaginitis atrofica, dispareunia peri- y posmenopausica, y/o mujeres ooforectomizadas y metodos de tratamiento con las mismas.

Info

Publication number
MX2017015235A
MX2017015235A MX2017015235A MX2017015235A MX2017015235A MX 2017015235 A MX2017015235 A MX 2017015235A MX 2017015235 A MX2017015235 A MX 2017015235A MX 2017015235 A MX2017015235 A MX 2017015235A MX 2017015235 A MX2017015235 A MX 2017015235A
Authority
MX
Mexico
Prior art keywords
compositions
treatment
peri
post
females
Prior art date
Application number
MX2017015235A
Other languages
English (en)
Inventor
M Christopher Anastasia
Original Assignee
Durga Entpr Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Durga Entpr Llc filed Critical Durga Entpr Llc
Publication of MX2017015235A publication Critical patent/MX2017015235A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A61K35/644—Beeswax; Propolis; Royal jelly; Honey
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Insects & Arthropods (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Botany (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)

Abstract

Se describen composiciones para administración tópica en un área urogenital y/o en la vagina. Las composiciones incluyen una cantidad terapéuticamente eficaz de un modulador selectivo de receptor de estrógenos (SERM), un portador intracelular para transportar el SERM a una célula, y una cantidad terapéuticamente eficaz de un agente antiinflamatorio celular. También se describen métodos para tratar la vaginitis atrófica, la dispareunia peri- y posmenopáusica, y/o las mujeres ooforectomizadas antes de la menopausia aplicando tópicamente tales composiciones al área urogenital y/o a la vagina.
MX2017015235A 2015-06-01 2016-06-01 Composiciones para el tratamiento de vaginitis atrofica, dispareunia peri- y posmenopausica, y/o mujeres ooforectomizadas y metodos de tratamiento con las mismas. MX2017015235A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562169105P 2015-06-01 2015-06-01
US201562255059P 2015-11-13 2015-11-13
PCT/US2016/035231 WO2016196608A1 (en) 2015-06-01 2016-06-01 Compositions for treatment of atrophic vaginitis, peri-and post-menopausal dyspareunia, and/or oophorectomized females and treatment methods therewith

Publications (1)

Publication Number Publication Date
MX2017015235A true MX2017015235A (es) 2018-04-11

Family

ID=57396949

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017015235A MX2017015235A (es) 2015-06-01 2016-06-01 Composiciones para el tratamiento de vaginitis atrofica, dispareunia peri- y posmenopausica, y/o mujeres ooforectomizadas y metodos de tratamiento con las mismas.

Country Status (9)

Country Link
US (2) US20160346336A1 (es)
EP (2) EP3854382B1 (es)
KR (1) KR20180023909A (es)
AU (1) AU2016270753B2 (es)
CA (1) CA2985383C (es)
ES (2) ES2965820T3 (es)
IL (1) IL256049A (es)
MX (1) MX2017015235A (es)
WO (1) WO2016196608A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2646453C1 (ru) * 2017-02-15 2018-03-05 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский радиологический центр" Министерства здравоохранения Российской Федерации Способ лечения атрофического вагинита
US10959450B2 (en) * 2017-10-15 2021-03-30 Yu Heong Jun Food composition for relieving symptoms of allergic and autoimmune diseases
CN109453278A (zh) * 2018-12-25 2019-03-12 赵显梁 一种外用抑菌中药颗粒及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1029456C (zh) * 1989-07-28 1995-08-09 蔡健 用于外阴的阴道润滑剂的制备方法
US5461064A (en) * 1993-12-21 1995-10-24 Eli Lilly And Company Methods of inhibiting atrophy of the skin and vagina
US5980875A (en) * 1996-04-12 1999-11-09 Mousa; Mahmoud A. Honey preparations
US6835750B1 (en) * 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
US7820145B2 (en) * 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
NZ551340A (en) * 2004-04-22 2010-10-29 Boehringer Ingelheim Int Pharmaceutical composition comprising flibanserin and a melanocortin agonist for the treatment of premenstrual disorder or sexual aversion disorder
EP2034984A4 (en) * 2006-06-02 2013-03-06 Pear Tree Women S Health Care PROCESS FOR TREATING ATROPHIC VAGINITIS
WO2015030609A1 (en) * 2013-08-30 2015-03-05 Apimed Medical Honey Limited Anti-inflammatory compositions, methods and uses thereof

Also Published As

Publication number Publication date
US20160346336A1 (en) 2016-12-01
CA2985383C (en) 2023-01-03
CA2985383A1 (en) 2016-12-08
ES2865254T3 (es) 2021-10-15
KR20180023909A (ko) 2018-03-07
EP3854382B1 (en) 2023-10-04
WO2016196608A1 (en) 2016-12-08
ES2965820T3 (es) 2024-04-17
EP3302474B1 (en) 2021-03-17
AU2016270753A1 (en) 2017-11-16
EP3854382A1 (en) 2021-07-28
EP3302474A4 (en) 2019-06-26
US20190282627A1 (en) 2019-09-19
IL256049A (en) 2018-01-31
AU2016270753B2 (en) 2021-06-17
EP3302474A1 (en) 2018-04-11

Similar Documents

Publication Publication Date Title
MX2018012486A (es) Composiciones para aplicacion topica de compuestos.
NI201900019A (es) Inhibidores de procesos metabólicos celulares
MX2018006578A (es) Formulaciones farmaceuticas topicas para tratar afecciones inflamatorias.
CR20190478A (es) Inhibidores de pd-1/pd-l1
CO2018001375A2 (es) Composiciones de retinoides tópicos
MX2017015990A (es) Composiciones topicas que comprenden un corticosteroide y un retinoide para tratar psoriasis.
SG10201906471PA (en) Treatment of cancer with anti-lap monoclonal antibodies
PH12016500649A1 (en) Combinations of histone deactylase inhibitors and immunomodulatory drugs
CL2019001565A1 (es) Composición farmacéutica para prevenir o tratar el cáncer, comprendiendo el polímorfo cristalino del hexoxido tetraarsénico.
MX2017015235A (es) Composiciones para el tratamiento de vaginitis atrofica, dispareunia peri- y posmenopausica, y/o mujeres ooforectomizadas y metodos de tratamiento con las mismas.
PH12014502441A1 (en) Topical non-aqueous pharmaceutical formulations
WO2014188276A3 (en) Antioxidant compositions and methods of using the same
MX353713B (es) Composiciones de administracion dermica y metodos.
EA201692334A1 (ru) Кортикостероидные композиции для местного применения
EA201791921A1 (ru) Композиции для местного применения, содержащие кортикостероид
CL2009001011A1 (es) Uso del compuesto 21-metoxi-17a-acetoxi-11ß-(4-n,n­-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona (cdb-4124) para tratar el cancer de mama; y uso de la combinacion de cdb-4124 con un inhibidor de aromatasa.
IL277692A (en) Topical and injectable cannabinoid preparations, kits and methods for treating skin wounds, and their uses
EP3162372A4 (en) Composition for treating ischemic diseases or neurogenic inflammation, containing, as active ingredient, neural progenitor cells or secretome thereof
MX2018000264A (es) Formulaciones topicas de diacereina de rheina y sus usos.
DOP2015000137A (es) Dispersión sólida de un modulador selectivo de los receptores de progesterona
MX2016003951A (es) Composicion para rocio topica de halobetasol.
TN2020000009A1 (en) Estrogen receptor modulators
MX2017011018A (es) Inhibicion de la actividad de olig2.
ZA201901367B (en) Inhibition of olig2 activity
CL2012002544A1 (es) Compuestos derivados de esteroides, inhibidores de la acción de la progesterona; composición farmacéutica; método para producir un efecto antiprogestacional; y método para tratar una afección dependiente de la progesterona tal como endometriosis y dolor asociado a esta, dismenorrea, fibromas uterinos y cáncer de ovario, entre otras.